NASDAQ:GTXI GTX (GTXI) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.30▼$0.3350-Day Range$1.20▼$7.2052-Week Range$0.74▼$25.60Volume135,722 shsAverage Volume390,540 shsMarket Capitalization$7.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About GTX (NASDAQ:GTXI) StockGTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.Read More GTXI Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comAcasti Announces $7.5 Million Private Placement Equity FinancingSeptember 22, 2023 | msn.comDanner Closes the Loop With Recraftable Boots: The Mountain 600 Leaf GTXSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 21, 2023 | msn.comAdidas Terrex Free Hiker 2 GTX boots review: urban meets outdoorsSeptember 20, 2023 | finanznachrichten.deHalberd Corporation: Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury Monitoring and Applications for Government ContractsSeptember 20, 2023 | msn.comNew Kia Seltos variants with ADAS to have significantly lower waiting periodSeptember 20, 2023 | finance.yahoo.comHalberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government ContractsSeptember 16, 2023 | msn.comSave Now as Much as $250 on CyberPowerPC Gaming DesktopsSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 14, 2023 | yahoo.comThese Comfy Sneakers Are Beloved By Older Women — And They're 35% Off Right NowSeptember 14, 2023 | yahoo.comTrès Rasché's Take on Reebok's Zig Kinetica Edge GTX is Feminine and FuriousSeptember 13, 2023 | msn.comGear Review: Rev'It! Discovery GTX BootsSeptember 12, 2023 | msn.comMO Tested: REV'IT! Stratum GTX ReviewSeptember 8, 2023 | msn.comVolkswagen ID.X Performance Concept Debuts: A 550-HP EV With Aggressive AeroSeptember 6, 2023 | msn.comVolkswagen ID.3 GTX Spied For The First Time, Should Debut In 2024September 2, 2023 | msn.com2024 Volkswagen ID. Buzz GTX Looks Like A Hyper-Bus At The NurburgringAugust 31, 2023 | msn.comVolkswagen ID. Buzz GTX Spied Testing On The NurburgringAugust 28, 2023 | msn.comThe Best PCs Builds To Play Armored Core 6: Fires Of RubiconAugust 26, 2023 | msn.comEvery Volkswagen Electric Car Coming Before 2030August 22, 2023 | finance.yahoo.comInvesting in Garrett Motion (NASDAQ:GTX) three years ago would have delivered you a 13% gainAugust 20, 2023 | msn.comVW ID.5 GTX review: an ideal family EVAugust 19, 2023 | msn.comVolkswagen ID. Buzz GTX Gets Camo-less Nurburgring ShakedownAugust 18, 2023 | msn.comSee 10 Future Cars In Spy Shots For The Week Of August 14, 2023August 17, 2023 | msn.comVW's hotted-up electric Kombi hits the trackAugust 15, 2023 | msn.comVolkswagen ID. Buzz GTX Long-Wheelbase Spied Without CamouflageAugust 14, 2023 | msn.comArmored Core 6 Reveals PC Spec RequirementsAugust 13, 2023 | msn.comHanwag Makra Trek GTX review: an aggressive hiker fit for technical scramblesSee More Headlines Receive GTXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GTX and its competitors with MarketBeat's FREE daily newsletter. Email Address GTXI Company Calendar Last Earnings11/15/2018Today9/27/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GTXI CUSIP40052B10 CIK1260990 Webwww.gtxinc.com Phone901-523-9700FaxN/AEmployees21Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-104.19% Return on Assets-86.42% Debt Debt-to-Equity RatioN/A Current Ratio12.39 Quick Ratio12.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book0.28Miscellaneous Outstanding Shares24,050,000Free FloatN/AMarket Cap$7.46 million OptionableOptionable Beta2.22 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Robert James Wills B.S. (Age 65)M.S., Ph.D., Exec. Chairman Mr. Marc S. Hanover (Age 56)Co-Founder, CEO & Director Mr. Henry P. Doggrell (Age 70)VP, Chief Legal Officer & Sec. Mr. Jason T. Shackelford (Age 44)VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller Dr. Diane C. Young (Age 62)VP & Chief Medical Officer Key CompetitorsCatalyst BiosciencesNASDAQ:CBIORegulus TherapeuticsNASDAQ:RGLSAthersysNASDAQ:ATHXPulmatrixNASDAQ:PULMAptorum GroupNASDAQ:APMView All Competitors GTXI Stock - Frequently Asked Questions How were GTX's earnings last quarter? GTx, Inc. (NASDAQ:GTXI) posted its quarterly earnings data on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.09. What other stocks do shareholders of GTX own? Based on aggregate information from My MarketBeat watchlists, some companies that other GTX investors own include Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL) and Amarin (AMRN). What is GTX's stock symbol? GTX trades on the NASDAQ under the ticker symbol "GTXI." What is GTX's stock price today? One share of GTXI stock can currently be purchased for approximately $0.31. How much money does GTX make? GTX (NASDAQ:GTXI) has a market capitalization of $7.46 million. The biopharmaceutical company earns $-38,420,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. How can I contact GTX? GTX's mailing address is 17 W Pontotoc Ave. Suite 100, MEMPHIS TN, 38103. The official website for the company is www.gtxinc.com. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at investor.relations@gtxinc.com. This page (NASDAQ:GTXI) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GTx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.